CGS-CIMB sees decent earnings growth for Pharmaniaga, reiterates ‘add’ call

KUALA LUMPUR, June 28 — CGS-CIMB Securities Sdn Bhd is positive on Pharmaniaga Bhd on the expectation of a decent financial year 2023-2024 earnings growth for the company.

“The ample excess production capacity at Pharmaniaga’s existing plants will allow it to ramp up output in the next three to five years — in light of rising pharmaceutical demand and new product launches — with little to no incremental capital expenditure, thus potentially leading to better economies of scale and margins,” it said.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

V S Industry’s counter measures prove effectivePETALING JAYA: V S Industry Bhd is projected to sustain a positive outlook on revenue growth despite rising cost pressures and labour shortages, which had caused a decline in its operating efficiency.
출처: staronline - 🏆 4. / 75 더 많은 것을 읽으십시오 »